Early diagnostic value of survivin and its alternative splice variants in breast cancer

BMC Cancer

Salma Khan¹  Heather Ferguson Bennit¹  David Turay¹  Mia Perez³  Saied Mirshahidi²  Yuan Yuan⁴  Nathan R Wall¹ 

[1] Center for Health Disparities & Molecular Medicine, Loma Linda University School of Medicine, 11085 Campus Street, Mortensen Hall Room 160, Loma Linda, CA 92350, USA

[2] Department of Medicine and LLU Cancer Center & San Manuel Band of Mission Indians Biospecimen Laboratory, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA

[3] Department of Pathology & Laboratory Medicine, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA

[4] Division of Medical Oncology & Therapeutics, City of Hope Medical Center, Duarte, CA 91010, USA

关键词: Breast cancer;    Exosomes;    Splice variants;    Survivin;   

Others  :  858980
DOI  :  10.1186/1471-2407-14-176

 received in 2013-04-29, accepted in 2014-02-28,  发布年份 2014

【 摘 要 】

Background

The inhibitor of apoptosis (IAP) protein Survivin and its splice variants are differentially expressed in breast cancer tissues. Our previous work showed Survivin is released from tumor cells via small membrane-bound vesicles called exosomes. We, therefore, hypothesize that analysis of serum exosomal Survivin and its splice variants may provide a novel biomarker for early diagnosis of breast cancer.

Methods

We collected sera from forty breast cancer patients and ten control patients who were disease free for 5 years after treatment. In addition, twenty-three paired breast cancer tumor tissues from those same 40 patients were analyzed for splice variants. Serum levels of Survivin were analyzed using ELISA and exosomes were isolated from this serum using the commercially available ExoQuick kit, with subsequent Western blots and immunohistochemistry performed.

Results

Survivin levels were significantly higher in all the breast cancer samples compared to controls (p < 0.05) with exosome amounts significantly higher in cancer patient sera compared to controls (p < 0.01). While Survivin and Survivin-∆Ex3 splice variant expression and localization was identical in serum exosomes, differential expression of Survivin-2B protein existed in the exosomes. Similarly, Survivin and Survivin-∆Ex3 proteins were the predominant forms detected in all of the breast cancer tissues evaluated in this study, whereas a more variable expression of Survivin-2B level was found at different cancer stages.

Conclusion

In this study we show for the first time that like Survivin, the Survivin splice variants are also exosomally packaged in the breast cancer patients’ sera, mimicking the survivin splice variant pattern that we also report in breast cancer tissues. Differential expression of exosomal-Survivin, particularly Survivin-2B, may serve as a diagnostic and/or prognostic marker, a “liquid biopsy” if you will, in early breast cancer patients. Furthermore, a more thorough understanding of the role of this prominent antiapoptotic pathway could lead to the development of potential therapeutics for breast cancer patients.

【 授权许可】

   
2014 Khan et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Sohn DM, Kim SY, Baek MJ, Lim CW, Lee MH, Cho MS, Kim TY: Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacother 2006, 60(6):289-292.
• [2]Al Dhaheri Y, Eid A, AbuQamar S, Attoub S, Khasawneh M, Aiche G, Hisaindee S, Iratni R: Mitotic arrest and apoptosis in breast cancer cells induced by Origanum majorana extract: upregulation of TNF-alpha and downregulation of survivin and mutant p53. PLoS One 2013, 8(2):e56649.
• [3]Rakha EA: Pitfalls in outcome prediction of breast cancer. J Clin Pathol 2013, 66(6):458-464.
• [4]Pennati M, Folini M, Zaffaroni N: Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008, 12(4):463-476.
• [5]van ‘t Veer LJDH, an de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536.
• [6]Ryan B, O’Donovan N, Browne B, O’Shea C, Crown J, Hill AD, McDermott E, O’Higgins N, Duffy MJ: Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 2005, 92(1):120-124.
• [7]Boidot R, Vegran F, Lizard-Nacol S: Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Int J Mol Med 2009, 23(2):285-291.
• [8]Span PN, Tjan-Heijnen VC, Sweep FC: Is survivin expression nevertheless related to disease outcome in breast cancer? Breast Cancer Res Treat 2007, 103(1):109.
• [9]Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD: Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999, 59(24):6097-6102.
• [10]Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura RA: Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005, 24(12):1994-2007.
• [11]Koike H, Sekine Y, Kamiya M, Nakazato H, Suzuki K: Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. Urology 2008, 72(6):1229-1233.
• [12]Khan S, Jutzy JMS, Aspe JR, McGregor DW, Neidigh JW, Wall NR: Survivin is released from cancer cells via exosomes. Apoptosis 2011, 16:1-12.
• [13]Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR: Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One 2012, 7(10):e46737.
• [14]Khan S, Jutzy JMS, Aspe JR, Valenzuela MMA, Park J, Turay D, Wall NR: The application of membrane vesicles for cancer therapy. Book 3, Advances in Cancer Therapy, InTech Publishing 2011, 21-52. http://www.intechopen.com/articles/show/title/the-application-of-membrane-vesicles-for-cancer-therapy webcite
• [15]Savina A, Furlan M, Vidal M, Colombo MI: Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem 2003, 278:20083-20090.
• [16]Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH, Bose S: PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 2004, 112(3):407-410.
• [17]Zeestraten EC, Benard A, Reimers MS, Schouten PC, Liefers GJ, van de Velde CJ, Kuppen PJ: The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry. Biomark Cancer 2013, 5:13-29.
• [18]Selemetjev S, Dencic TI, Marecko I, Jankovic J, Paunovic I, Savin S, Cvejic D: Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma. Pathol Res Pract 2013, 210(1):30-34.
• [19]Jeon C, Kim M, Kwak C, Kim HH, Ku JH: Prognostic role of survivin in bladder cancer: a systematic review and meta-analysis. PLoS One 2013, 8(10):e76719.
• [20]Vegran F, Mary R, Gibeaud A, Mirjolet C, Collin B, Oudot A, Charon-Barra C, Arnould L, Lizard-Nacol S, Boidot R: Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy. Cancer Res 2013, 73(17):5391-5401.
• [21]Marimpietri D, Petretto A, Raffaghello L, Pezzolo A, Gagliani C, Tacchetti C, Mauri P, Melioli G, Pistoia V: Proteome profiling of neuroblastoma-derived exosomes reveal the expression of proteins potentially involved in tumor progression. PLoS One 2013, 8(9):e75054.
• [22]O’Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, McDonnell S, Crown J, Radomski MW, O’Driscoll L: Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer 2013, 49(8):1845-1859.
• [23]Islam A, Kageyama H, Hashizume K, Kaneko Y, Nakagawara A: Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med Pediatr Oncol 2000, 35(6):550-553.
• [24]Ge QX, Li YY, Nie YQ, Zuo WG, Du YL: Expression of survivin and its four splice variants in colorectal cancer and its clinical significances. Med Oncol 2013, 30(2):535.
• [25]Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S: BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the children’s oncology group. Pediatr Blood Cancer 2013, 61(4):647-652.
• [26]Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD: Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 2002, 86(5):737-743.
• [27]Meng H, Lu CD, Sun YL, Dai DJ, Lee SW, Tanigawa N: Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J Gastroenterol 2004, 10(22):3245-3250.